



SET YOUR SIGHTS ON THE BEST SITES FOR YOUR PAEDIATRIC TRIALS!



Identifying the best sites directly impacts time to **study completion, quality, cost and success**. An extra challenge for paediatric trials is the very limited number of patients, often requiring multiple capable sites.

CONECT4CHILDREN STICHTING (C4C-S) CAN SUPPORT PAEDIATRIC STUDIES TO:

- overcome challenging and time-consuming **site feasibility assessments** through optimised processes.
- streamline **Confidential Disclosure Agreement (CDA) completion and signatures** through simplified and standardised procedures.
- benefit from **solutions tailored to multinational study design**.

C4C-S HAS CREATED A NETWORK OF QUALITY SITES AND SERVICES TO SUPPORT YOUR PAEDIATRIC CLINICAL TRIALS:

SITE IDENTIFICATION

c4c-S's Single Point of Contact (SPoC) and comprehensive database-driven search can make the process of identification more efficient and user friendly, **speeding up the process to 4 to 6 weeks**.


SITE FEASIBILITY

Choose from a large network of **over 250 clinical sites across 21 countries**.

CDAs can be obtained much faster thanks to a **unique, leaner CDA cascade approach** and a harmonised feedback process only requiring **one sponsor signature**.

STUDY SUPPORT


The network's expertise, close relationship with the sites and insight into local complexities and regulations **keep studies on track, detect issues, troubleshoot and shorten timelines**.



c4c-S has worked with academic-based institutions with **strong links to the national paediatric research** and clinical communities in different countries to create National Hubs (NHs). The NHs ensure a **close, trustworthy relationship with clinical sites and local stakeholders**.

c4c-S has 20 NHs covering 21 countries in Europe.

The international network of NHs and sites ensures a **local representation across Europe** and provides the necessary insights to navigate the **cultural differences and regulatory complexities between regions** that are inherent to multinational trials.



Stay informed about c4c-S:
c4c.spoc@conect4children.eu

Certain information in this communication contains forward-looking statements, including statements related to the expected scope and timing of launch of services, as well as the number of countries and/or sites at time of launch of related services based upon what we believe are reasonable assumptions.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389.

The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

This publication reflects the authors' views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

